Cristina Escorial Moya

Dr. Cristina Escorial Moya

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Revista Clínica Española
Verified
Journal Article
Closed access
AMA. Fernández Moyano
A. Fernández Moyano
JGJosé Luis García Garmendia
José Luis García Garmendia
CPC. Palmero Palmero
C. Palmero Palmero
BVB. García Vargas-Machuca
B. García Vargas-Machuca
JPJ.M. Páez Pinto
J.M. Páez Pinto
IMI. Vallejo Maroto
I. Vallejo Maroto

Verified
Journal Article
Open access
PDF file
JDJuan Delgado-Cuesta
Juan Delgado-Cuesta
CMCristina Escorial Moya
Cristina Escorial Moya
AVAntonio Vallejo-Vaz
Antonio Vallejo-Vaz
BSBernardo Santos-Ramos
Bernardo Santos-Ramos
JVJose M. Varela
Jose M. Varela
FMFrancisco J Medrano
Francisco J Medrano
Objective: The objective of this study was to compare the effectiveness of urea and tolvaptan in the treatment of plasma sodium levels in patients with hypotonic hyponatremia. Methods: This was an observational, longitudinal, and retrospective study including all adult patients who received treatment with urea or tolvaptan for hypotonic hyponatremia from 1 April 2014 to 31 October 2023 at the Department of Internal Medicine, Virgen del Rocío University Hospital, Seville, Spain. Results: Forty-seven (55.3%) patients received urea and 38 (44.7%) tolvaptan. The drugs were prescribed for the treatment of syndrome of inappropriate antidiuresis (SIAD) in 59 (69.4%) patients. The mean blood sodium level at the start of treatment was 123.5 ± 6.2 mEq/L. Overall, 61.7% and 63.2% of patients treated with urea and tolvaptan, respectively, achieved a normal blood sodium level (p = 0.89), although the time to have their sodium levels corrected differed between both groups: 41.7 ± 76 days with urea and 21 ± 23.9 days with tolvaptan (p = 0.038). The following were significant in the multivariate study: Initial sodium value (p = 0.037), absolute sodium improvement (p = 0.041), and percentage sodium improvement (p = 0.033). Among patients with SIAD, 69.5% achieved a normal sodium level; this figure was 45.5% for patients with heart failure. Three patients reported side adverse events in the urea group and none in the tolvaptan group. Conclusions: Our data, reflecting real-world practice and follow-up of patients with hypotonic hyponatremia, suggest that both urea and tolvaptan are safe, well-tolerated, and have a similar effectiveness in correcting blood sodium levels in patients with hypotonic hyponatremia, overall and secondary to SIAD, though treatment with tolvaptan achieved this goal earlier than urea.

1 November 2011 in Revista Clínica Española
Verified
Journal Article
Closed access
CMCristina Escorial Moya
Cristina Escorial Moya
MMMaría-José Montoya-García
María-José Montoya-García
MVM. Angeles Vázquez-Gámez
M. Angeles Vázquez-Gámez
MGM. Giner-García
M. Giner-García
CMC. Miranda-Díaz
C. Miranda-Díaz
RPR. Pérez-Cano
R. Pérez-Cano

5 July 2025 in Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
Yale Tung-ChenYale Tung-Chen
Yale Tung-Chen
FMFrancisco Javier Teigell Muñoz
Francisco Javier Teigell Muñoz
SBSergio Aleman Belando
Sergio Aleman Belando
BFBosco Barón Franco
Bosco Barón Franco
LRLuis Matías Beltrán Romero
Luis Matías Beltrán Romero
JPJosé M. Porcel
José M. Porcel

1 March 2004
Verified
Journal Article
Closed access
CMCristina Escorial Moya
Cristina Escorial Moya
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
MBM Victoria Borobio
M Victoria Borobio
GIG Izquierdo
G Izquierdo